Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05183087
Other study ID # 2020P002695
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 1, 2021
Est. completion date February 28, 2023

Study information

Verified date April 2023
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a pilot study to identify biomarkers that individually, and in combination, demonstrate the greatest sensitivity to repetitive, low-level blast exposure (RLLBE) neurotrauma in Special Operations Forces (SOF) personnel. The proposed cross-sectional, multimodal study will elucidate the potential effects of long-term RLLBE by comparing biomarkers across subjects.


Description:

The proposal includes a comprehensive battery of assessments characterized by high-field neuroimaging, proteomics, and experimental cognitive and neurobehavioral evaluations, which will be implemented alongside standardized clinical diagnostic tools. The results will inform the design of a larger trial to validate the diagnostic utility of these biomarkers as well as their ability to predict RLLBE-related clinical outcomes. A secondary aim will be to define the underlying mechanisms, risk and resilience factors, and clinical phenotypes associated with RLLBE. Biomarkers assessed over the course of a two-day evaluation will include: 1. 3 Tesla Connectome MRI to detect structural disruption of brain networks 2. 7 Tesla MRI to detect functional disruption of brain networks 3. Translocator protein (TSPO) PET - ligand [11C]-PBR28 to detect neuroinflammation 4. Tau PET - ligand [18F]-MK6240 to detect tau deposition 5. Neurocognitive assessments to detect signs of cognitive/behavioral dysfunction 6. Self-report indicators of cognitive/behavioral dysfunction 7. Blood biomarkers to detect evidence of blast injury using proteomics and metabolomics We hypothesize that a multimodal assessment using Connectome MRI, 7 Tesla MRI, TSPO PET, Tau PET, cognitive/behavioral tests, proteomics and metabolomics will identify biomarkers of RLLBE-related brain injury.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date February 28, 2023
Est. primary completion date February 28, 2023
Accepts healthy volunteers No
Gender Male
Age group 25 Years to 45 Years
Eligibility Inclusion Criteria: 1. Adults aged 25-45 years of age 2. Males, regardless of race or ethnicity 3. Active duty Special Operation Forces 4. History of combat deployment confirmed by Veterans Affairs (VA) or Department of Defense (DOD) records (defined as: while serving in the U.S. military, individual was deployed to a region of conflict) 5. History of combat exposure during any deployment as measured by endorsement of any item on the Combat Exposure Scale (CES) Exclusion Criteria: 1. History of moderate or severe traumatic brain injury (TBI) (using the VA/DOD definition: initial Glasgow Coma Scale score < 13, coma duration > ½ hr, post-traumatic amnesia duration > 24 hr, or abnormal structural brain imaging) 2. History of major neurologic disorder such as stroke or spinal cord injury resulting in a significant decrement in functional status or loss of independent living capacity 3. Untreated or unstable severe psychiatric condition (e.g., schizophrenia or bipolar disorder) that is likely to impact study participation or ability to complete study procedures 4. Current severe medical condition (excluding currently diagnosed mild TBI or concussion) that requires long-term treatments (e.g., cancer, diabetes mellitus, human immunodeficiency virus, autoimmune disorders) 5. Any cardiac, respiratory, or other medical condition that may affect cerebral metabolism 6. Benzodiazepines other than lorazepam, desmethyldiazepam and oxazepam within past month 7. MRI contraindications 1. Metal in the body that would make an MRI scan unsafe, such as pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent eye liner or small metal fragments in the eye 2. Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest 3. Inability to lie supine for up to 2 hours in the MRI scanner, as assessed by physical examination and medical history (e.g., back pain, arthritis) 4. > 300 lbs (weight limit of the MRI table) 8. Prior radiation exposure of = 50 mSv over the past 12 months, in the context of research, as determined by review of DOD medical records (e.g., prior imaging studies) and self-report 9. Any condition which, in the opinion of the Principal Investigator, may cause undue risk to the subject 10. Other: Any condition or characteristic that in the judgment of the Principal Investigator would create a logistical or safety contraindication to enrollment (e.g., shoulder width greater than the bore of the MRI or PET/MRI machines)

Study Design


Intervention

Diagnostic Test:
3T Connectome MRI
MRI scan of structural connectivity
7 Tesla MRI
MRI scan of functional connectivity
TSPO PET
PET scan of neuroinflammation
Tau PET
PET scan of tau deposition
Cognitive and Behavioral Assessments
Assessments of memory, attention, complex reasoning, mood and other cognitive/behavioral domains
Blood Biomarkers
Blood-based assessments of proteomic and metabolic biomarkers of brain injury

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diffusion MRI structural connectivity measured by white matter tractography Day 1
Primary fMRI resting state functional connectivity measured by default mode network connectivity Day 2
Primary PET Neuroinflammation measured by standardized uptake value ratio of TSPO ligand [11C]PBR28 Day 1
Primary PET Tau deposition measured by standardized uptake value ratio of [18F]MK6240 Day 2
Primary Neurofilament Light Chain measured by serum concentration of neurofilament light chain Day 1, after 6-8 hour fasting
Primary Cognitive Function measured by the Trail Making Test Day 1
Primary Behavioral symptoms measured by the Neurobehavioral Symptom Inventory Day 2
Primary Physical symptoms measured by the Neurobehavioral Symptom Inventory Day 2
See also
  Status Clinical Trial Phase
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05503316 - The Roll of Balance Confidence in Gait Rehabilitation in Persons With a Lesion of the Central Nervous System N/A
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Terminated NCT03698747 - Myelin Imaging in Concussed High School Football Players
Recruiting NCT05130658 - Study to Improve Ambulation in Individuals With TBI Using Virtual Reality -Based Treadmill Training N/A
Recruiting NCT04560946 - Personalized, Augmented Cognitive Training (PACT) for Service Members and Veterans With a History of TBI N/A
Completed NCT05160194 - Gaining Real-Life Skills Over the Web N/A
Recruiting NCT02059941 - Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines N/A
Recruiting NCT03940443 - Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Completed NCT04465019 - Exoskeleton Rehabilitation on TBI
Recruiting NCT04530955 - Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS) N/A
Recruiting NCT03899532 - Remote Ischemic Conditioning in Traumatic Brain Injury N/A
Suspended NCT04244058 - Changes in Glutamatergic Neurotransmission of Severe TBI Patients Early Phase 1
Completed NCT03307070 - Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury N/A
Recruiting NCT04274777 - The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders
Withdrawn NCT05062148 - Fundamental and Applied Concussion Recovery Modality Research and Development: Applications for the Enhanced Recovery N/A
Withdrawn NCT04199130 - Cognitive Rehabilitation and Brain Activity of Attention-Control Impairment in TBI N/A
Withdrawn NCT03626727 - Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia Early Phase 1